17^th World Congress on Advances in Stem Cell Research and Regenerative Medicine September 25-26, 2023 Zurich, Switzerland

1. Stem Cell: Our conference is focusing on latest advancement and discoveries in the field of stem cell and regenerative medicine. Stem cells are special human cells that are able to develop into many different cell types. This can range from muscle cells to brain cells.

       Stem cell | Embryonic stem cells| Adult stem cells | Molecular biology | Cell Biology | Regenerative medicine.

2. Regenerative medicine: Regenerative medicine deals with the "process of replacing, engineering or regenerating human or animal cells, tissues or organs to restore or establish normal function". Stem cell therapy is considered a safe and effective treatment option for many conditions, and many clinical trials have shown promising results. In our conference we will discuss newly discovered concepts in regenerative medicine and stem cell treatments.

3. Tissue Engineering: The goal of tissue engineering is to assemble functional constructs that restore, maintain, or improve damaged tissues or whole organs. Artificial skin and cartilage are examples of engineered tissues that have been approved by the FDA; however, currently they have limited use in human patients. Tissue engineering is a new biotechnology which aims to generate autologous tissue graft with an engineering approach.

4. Bio-informatics in Stem Cell Research: Bioinformatics frameworks developed in recent years that will facilitate analysis and promote the application of stem cells to medical research. The stem cell bioinformatics uses computational methods to explore the molecular mechanisms underpinning stem cells and will accelerate the application of these stem cells to regenerative medicine.

5. 3D Bio-Printing and Organ Printing: Engineering, manufacturing, art, education, and medicine are just a few of the fields where three-dimensional (3D) printing is driving substantial changes. Biocompatible materials, cells, and supporting components can now be 3D printed into complex 3D functioning living tissues, thanks to recent advancements. To meet the demand for transplantable tissues and organs, 3D bio printing is being used in regenerative medicine. 3D bio printing has more complexities than non-biological printing, such as material selection, cell kinds, growth and differentiation variables, and technical obstacles associated to living cell sensitivities and tissue assembly. Engineering, biomaterials science, cell biology, physics, and medicine must all work together to solve these problems. Bio printing in 3D has already been used to create and test new drugs.

• 3D-bioprinted tissue models
• Inkjet based 3D Bio printing
• Extrusion based 3D Bio printing
• Laser assisted 3D Bio printing
• Stereolithographic based 3D Bio printing

6. Cancer Stem Cells: Cancer stem cells (CSCs) are a subpopulation of tumour cells that can drive tumour initiation and can cause relapses. At the time point of tumour initiation, CSCs originate from either differentiated cells or adult tissue resident stem cells.

• Cancer somatic cell and neoplasm Biology
• Cancer genetics and metabolomics
• Radiation medical specialty
• Biomarker in cancer somatic cells
• Novel Cancer stem cell (CSC) regulative Mechanism

7. Fetal and Neonatal Stem Cells: The neonatal stem cells are collected from placental tissues and cord blood. The stem cells are made up of mesenchyme and hematopoietic cells, which are multipotent cells. Fetal and Neonatal Stem Cells can be used to test a drug's ability to damage genetic material or to test the effects of specific viral (or other types) of infection.

8. Regenerative Medicine and Surgery: As the population ages, there is an increasing need for organ and tissue replacement to cope with the deterioration and disease of cardiovascular, gastrointestinal, kidney, and musculoskeletal organs. Transplantation of live and dead donor organs cannot currently meet this need. Regenerative medicine is an interdisciplinary field that incorporates stem cell biology, immunology, materials science, engineering, medicine, and surgery to develop solutions that can enhance or replace the regenerative capacity of the body's own tissues. With such a wide range of disciplines, it is important for different stakeholders to understand where the overall picture of the process of developing and clinically using regenerative medicine products fits. It also discusses recent surgical applications in regenerative medicine.

• Hand transplantation
• Face transplantation
• Lymphedema
• Preclinical modelling

9. Techniques in stem cell research: In our conference we will discuss the latest and advance techniques in steam cell.

• Immunomagnetic cell separation.
• Fluorescence-activated cell sorting (FACS)
• Density gradient centrifugation.
• Immunodensity cell isolation.
• Microfluidic cell sortin

10. Types of stem cells:

• Embryonic stem cells (ESC)
• Tissue specific progenitor stem cell(TSPSC)
• Mesenchymal stem cell(MSC)
• Induced pluripotent stem cells(IPSC)

11. Biomaterials in  bioengineering: Biomaterials is the field of study in which scientists engineer a substance to direct, through the use of living organisms, a therapeutic or diagnostic procedure. In BE, there are professors studying biomaterials to manipulate immune cells, to deliver drugs in novel ways, and to create complex tissue microstructures.

12. Tissue preservation and bio banking: The process by which samples of bodily fluid or tissue are collected for research use to improve our understanding of health and disease. There are various styles to save tissue and DNA samples that are well tested and frequently used including freezing, drying and storage in ethanol or buffer. Bio banking could be a type of biorespository that stores biological samples. Bio banks can give experimenters access to data representing an outsized number of people.

Report Overview

The global regenerative medicine market size was valued at USD 27.29 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.27% from 2022 to 2027. The emergence of gene therapy coupled with the developments in stem cell and tissue engineering are expected to fuel the market growth. In addition, increasing regulatory approvals for advanced therapy medicinal products have propelled the market growth. The ongoing COVID-19 pandemic created lucrative opportunities for the operating players owing to the urgent need for the development of new therapies against SARS-COV-2. Several initiatives are being implemented in the cell and gene therapy manufacturing industry, including the T-cell therapy space.

For instance, based on the previous research insights, Singapore-based Duke-NUS medical school’s emerging infectious diseases research program demonstrated the utility of these immunotherapies in treating patients with COVID-19 infection. The presence of several programs and continuous investments by government and private agencies to support R&D also accelerate the industry's progress. Like National Institutes of Health (NIH) supports the scientific research community through NIH Regenerative Medicine Program, NIH Stem Cell Libraries & Projects, NIH Stem Cell Unit, and others. Similarly, initiatives adopted by market players to raise finance for the R&D of regenerative medicine support the market progression.

In addition, companies are collaborating to strengthen their R&D capabilities to develop and commercialize innovative therapies to ensure their availability to their customers locally or worldwide. For instance, in July 2021, Pharming Group N.V. and Orchard Therapeutics collaborated for the development and commercialization of OTL-105, an investigational ex vivo autologous Hematopoietic Stem Cell (HSC) gene therapy for the treatment of Hereditary Angioedema (HAE).

Moreover, technological advancements in stem cell-based therapies have revolutionized the perspective of researchers toward regenerative medicine. Advances in stem cell therapy have accelerated the developments in regenerative medicine. For instance, haematogenic stem cells currently are being used to treat leukemia and blood disorders. Also, nanotechnology is a powerful tool for engineering stem cells and regenerative medicine. With the introduction of new technology, nanofabrication techniques can now allow researchers to develop nanofiber scaffolds.

Product Insights                            

The therapeutics segment accounted for the maximum revenue share of more than 56% in 2021 and is anticipated to continue its dominance throughout the forecast period. Among therapeutics vertical, primary cell-based therapies are the most developed therapeutics available due to their usage for different therapeutic indications and early adoption of these therapies in clinical application.

The stem cell &progenitor cell-based therapies segment is expected to register the fastest CAGR over the forecast years due to high investments in stem cell research coupled with redrafting in regulatory policies for their use in clinical applications. Allogenic stem cell-based therapies are estimated to account for the largest revenue share whereas autologous therapies are characterized with one of the fastest CAGRs.

Key vendors with specialized technology provide management, manufacturing, characterization, engineering, and quality control services along with other facilities for clinical trials and other research associated with the development of regenerative therapies. Hence, with a rise in R&D and clinical trials of regenerative medicines, the services segment is projected to witness rapid growth.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Competitive benchmarking
• Historical data & forecasts
• Company revenue shares
• Regional opportunities
• Latest trends & dynamics

Therapeutic Category Insights

The application of regenerative therapies is maximum in the oncology segment, thus, it captured the largest revenue share of more than 31% revenue share in 2021. High cancer prevalence has resulted in the implementation of efficient cancer treatment options. Various government organizations, as well as private companies, have made high investments in cancer research and the development of regenerative & advanced cell therapies. Global efforts to reduce the cancer burden are also anticipated to drive the segment growth.

On the other hand, the presence of a strong product portfolio coupled with increasing incidences of musculoskeletal disorders is anticipated to boost the revenue of the musculoskeletal segment. The introduction of efficient regenerative solutions in form of stem cells and tissue engineering to restore the tissues and regain functional strength has led to the rapid development of the segment. Safe and potentially officious treatments are available in regenerative and cell-based therapies for the segment.

Furthermore, various novel approaches in developmental phases promote tissue engineering. This includes the use of biomaterials and drug delivery systems, which stimulate and control the immune system and influence cell replication. Increased complexity of the wound healing process with severe diseases, such as diabetes and HIV, has encouraged R&D approaches in the dermatology segment.

Regional Insight

North America dominated the global market in 2021 with a revenue share of more than 45%. This is attributed to the presence of a significant number of key players in the U.S. The availability of advanced technologies and the presence of research institutes that are involved in the development of novel therapeutics are attributive to the high number of clinical trials in this region.

Availability of funds as well as several initiatives by the government & private organizations contributes to the highest revenue flow from the U.S. For instance, the “2020: A New Vision” initiative of the U.S. Department of Health and Human Services recognizes regenerative medicine at the forefront of healthcare.

Asia Pacific is predicted to witness the fastest CAGR over the forecast period owing to the expansion of infrastructure and facilities to accelerate stem cell research in the emerging economies of the region. In Japan, the Ministry of Health, Labor and Welfare approved Regenerative Medicine law in April 2013, which propelled the clinical development of regenerative and cell-based therapies. Similarly, the Chinese government has approved several research activities related to human embryonic stem cells that have encouraged researchers to explore the clinical potential of these cells.